ATIM-13. PHASE I STUDY OF CHIMERIC ANTIGEN RECEPTOR-ENGINEERED T CELLS TARGETING IL13Rα2 FOR THE TREATMENT OF GLIOBLASTOMA
Work
Year: 2016
Type: article
Abstract: T cell immunotherapy is emerging as a powerful strategy to treat cancer, and may offer opportunities to improve outcomes for patients with glioblastoma (GBM). We have optimized a chimeric antigen rece... more
Source: Neuro-Oncology
Institutions City Of Hope National Medical Center, City of Hope
Cites:
Cited by: 4
Related to: 10
FWCI: 0.445
Citation percentile (by year/subfield): 58.84
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze